Treatment of Central Sleep Apnea with Adaptive Servoventilation in Chronic Heart Failure

EDITORIALS Treatment of Central Sleep Apnea with Adaptive Servoventilation in Chronic Heart Failure Patients with chronic heart failure and systolic dysfunction are at increased risk of having central sleep apnea (CSA) and Cheyne- Stokes respiration, which are associated with hypoxemia, sleep fragmentation, and mortality (1). Positive pressure devices (adaptive servoventilation or autoservoventilation [ASV]) have been designed to treat CSA and are often used in this patient population. These devices provide ventilatory support during periods of central apneas and hypopneas. ASV has been shown to be effective in improving sleep apnea severity, sleep quality, and cardiac function in short-term clinical trials (2). Given these short- term benefits, long-term treatment was hypothesized to result in improvements in robust clinical endpoints in patients with CHF . The SERVE-HF study was designed to address this hypothesis. The rationale and design of this study are described elsewhere (3, ClinicalTrials.gov NCT00733343). In brief, patients with chronic (.12 wk) symptomatic heart failure (New York Heart Association Class III or IV at enrollment, or II with at least one hospitalization for CHF in the last 24 mo) due to systolic dysfunction (left ventricular ejection fraction 10/h, apnea–hypopnea index > 15/h, and .50% central events) were enrolled. Participants were randomized to either standard medical therapy without treatment of CSA, or standard medical therapy with the addition of ASV. The trial completed enrollment with over 1,300 patients recruited and with preliminary results reported (4). No significant difference in the primary composite outcome of all-cause mortality or unplanned hospitalizations was identified (hazard ratio = 1.14, 0.97–1.33 ; P = 0.10); however, cardiovascular mortality was increased in patients in the ASV arm compared with participants in the control arm with an absolute annual mortality rate of 10% versus 7.5% (HR = 1.34, 1.07–1.67; P = 0.010). Although final and more in-depth analyses are still pending, the excess risk appears to be driven by outpatient deaths (likely sudden cardiac deaths). The increased risk of death seemed to be independent of perceived benefit from the device, with no worsening of clinical symptoms or need for hospitalization prior to the event. The results of SERVE-HF are surprising and contrary to the preliminary data showing short-term benefits in symptoms and physiology. More insight into the potential mechanisms for the increased mortality in the ASV arm will hopefully be available once the final results of the study are published; though open for speculation, potential explanations could include imbalances in randomization, hemodynamic effects of positive pressure, potential benefits of CSA (5), or a proarrhythmogenic effect through metabolic/electrolyte abnormalities. At this point, it is unknown whether certain subgroups might be at greater risk (e.g., lower ejection fraction, patients without an implantable defibrillator), but more insight into these issues will likely be available once the final results are published. Field Safety Notice Because of the results, a field safety notice was issued by ResMed, Inc., on May 13, 2015, that provided a number of recommendations (4). Specifically, they recommended that ASV should not be started in patients with symptomatic CHF and left ventricular ejection fraction < 45%, that is, heart failure with reduced ejection fraction (HFrEF), who have predominantly central sleep apnea. Similarly, before considering placing patients on ASV to treat central sleep apnea, a clinical evaluation for the presence of CHF should be done. Patients with suggestive signs and symptoms should be sent for further evaluation for HFrEF, and patients with HFrEF should not be initiated on ASV. Patients with symptomatic HFrEF currently using an ASV machine should be identified and contacted urgently to discuss discontinuation of the device. Ultimately, the decision on whether to continue ASV should be a joint one between the patient and physician balancing risks and benefits, but stopping ASV should be strongly considered given the increased cardiovascular mortality observed in this group. There are, however, a number of additional questions related to clinical management that should be considered in the context of these trial results. How Should ASV Be Discontinued? Given that positive airway pressure reduces ventricular preload and afterload, abrupt discontinuation may result in an exacerbation of heart failure. We would recommend careful assessment of volume status at the time of discontinuation, as this information may help with the timing of positive airway pressure discontinuation and optimization of medical therapy. How Should CSA Be Managed in Patients in Whom ASV Is Discontinued? Certainly, therapies such as supplemental oxygen, acetazolamide, or continuous positive airway pressure (CPAP) can be useful to correct hypoxemia and improve sleep apnea (6). However, the long-term effects of these therapies are unknown and may not be beneficial; for example, in a recent trial, oxygen was found to be potentially detrimental in nonhypoxemic patients with myocardial infarction (7). Clearly, the priority is to ensure that patients have their heart failure medical management optimized. Am J Respir Crit Care Med Vol jj, Iss jj, pp 1–2, jj jj, 2015 Copyright © 2015 by the American Thoracic Society DOI: 10.1164/rccm.201506-1131ED Internet address: www.atsjournals.org Editorials

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.